Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01994174 · ClinicalTrials.gov registry record
Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
A clinical trial, sponsored by University of Nebraska.
- Terminated
- Registry status
- 13
- Enrollment target
NCT01994174: Clinical Trial study, sponsored by University of Nebraska.
NCT01994174 is a clinical trial that was terminated before completion, run by University of Nebraska. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01994174 was terminated before completion, sponsored by University of Nebraska.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.
Primary Outcome
The uveoscleral outflow changes will be assess at baseline prior to any anti-VEGF treatment and after the 3rd intravitreal treatment has been done.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-12-20 |
| Est. Completion | 2023-01-12 |
Why NCT01994174 stopped before completion
NCT01994174 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01994174 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01994174 about?
NCT01994174 is a clinical study titled "Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics". The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueo...
What is the current status of trial NCT01994174?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2013-12-20. Estimated completion is 2023-01-12.
Who is sponsoring clinical trial NCT01994174?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI